Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 4, April, p. 547–554

doi: 10.17219/acem/76847

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Systemic sclerosis and its oral health implications

Agata Puzio1,B,D,E,F, Brygida Przywara-Chowaniec2,B,C,D,E,F, Lidia Postek-Stefańska1,D,E,F, Katarzyna Mrówka-Kata3,B,D,E,F, Karolina Trzaska4,B,E

1 Department of Pediatric Dentistry, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland

2 2nd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland

3 Department of Otorhinolaryngology and Oncological Laryngology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland

4 Clinical Department of Internal Diseases, Dermatology and Allergology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland

Abstract

Systemic sclerosis (SSc) is a chronic, generalized disorder of the connective tissue. It is characterized by immune disorders, abnormalities of morphology and functions of small blood vessels, and the presence of inflammatory process. The pathogenesis of this disorder has not yet been fully understood. The classification criteria were established by The American College of Rheumatology (ACR). A number of clinical types are distinguished due to the diversity of the clinical picture. These types are characterized by a different course, presence of organ complications and prognosis. Connective tissue disorders are interdisciplinary conditions and, therefore, the subject of interest of different medical specialties, including dentistry. The oral cavity may be the place of pathological manifestations within soft and hard tissues. Such manifestations are the results or the primary symptom of systemic diseases. The relationship between the health of the oral cavity and systemic diseases has been frequently reported in the literature. Lesions in the oral cavity in patients with SSc are discussed in detail in the present paper. Management includes the administration of drugs that prevent tissue ischemia and post-ischemic consequences as well as drugs that inhibit inflammatory-immune processes and excessive collagen production.

Key words

connective tissue diseases, oral manifestations, systemic scleroderma

References (51)

  1. Kuźnik-Trocha K, Winsz-Szczotka K, Komosińska-Vassev K, Olczyk K. Twardzina układowa: Etiopatogeneza, diagnostyka, leczenie. Diagn Lab. 2012;48(4):441–451.
  2. Szymańska E, Maj M, Rudnicka L. Twardzina układowa: Przebieg kliniczny i możliwości terapeutyczne. Przegl Lek. 2005;62(12):1538–1541.
  3. Marcucci M, Abdala N. Clinical and radiographic study of orofacial alterations in patients with systemic sclerosis. Braz Oral Res. 2009; 23(1):82–88.
  4. Meissner M. Choroby tkanki łącznej: Co lekarz domowy powinien wiedzieć? Nowa Klin. 2009;16(1–2):21–31.
  5. Więsik-Szewczyk W, Olesińska M. Współczesny obraz twardziny układowej. Pol Merkur Lekarski. 2010;28(167):416–420.
  6. Krasowska D. Patogeneza, kryteria rozpoznawania i klasyfikacja twardziny układowej. Dermatologica. 2008;1(49):21–29.
  7. Burkhart NW. Scleroderma. Registered Dental Hygienist. 2009;29(6):58–61.
  8. Sierakowski S, Kowal-Bielecka O, Gindzieńska-Sieśkiewicz E. Twardzina układowa. Reumatologia. 2004;42(Suppl 1):59–69.
  9. Jung S, Martin T, Schmittbuhl M, Huck O. The spectrum of orofacial manifestations in systemic sclerosis: A challenging management. Oral Dis. 2017;23(4):424–439.
  10. Baron M, Hudson M, Tatibouet, et al. The Canadian systemic sclerosis oral health study: Orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with general population. Rheumatology (Oxford). 2014;53(8):1386–1394.
  11. Perno GM. Invisible illnesses: When the body turns on itself. CJDH. 2008;23(3):9–14.
  12. Dghoughi S, El Wady W, Taleb B. Systemic sclerosis case report and review of literature. N Y State Dent J. 2010;76(3):30–35.
  13. Albilia JB, Lam DK, Blanas N, Clokie CM, Sandor GK. Small mouths, big problem? A review of scleroderma and its oral health implications. J Can Dent Assoc. 2007;73(9):831–836.
  14. Chu CH, Yeung CM, Lai IA, Leung WK, Mok MY. Oral health of Chinese people with systemic sclerosis. Clin Oral Investig. 2011;15(6):931–939.
  15. Cazal C, Sobral AP, Neves RF, Freire Filho FW, Cardoso AB, da Silveira MM. Oral complaints in progressive systemic sclerosis: Two cases reports. Med Oral Patol Oral Cir Bucal. 2008;13(2):114–118.
  16. Ferreira E, Christmann RB, Borba EF, Borges CT, Siqeira JT, Bonfa E. Mandibular function is severely impaired in systemic sclerosis patients. J Orofac Pain. 2010;24(2):197–202.
  17. Maddali Bongi S, Del Rosso A, Gallucio F, et al. Efficacy of a tailored rehabilitation program for systemic sclerosis. Clin Exp Rheumatol. 2009;27(3 Suppl 54):44–50.
  18. Dixit S, Kalkur C, Sattur AP, Bornstein MM, Felton F. Scleroderma and dentistry: Two case reports. J Med Case Rep. 2016;10(1):297.
  19. Comstedt L, Svensson A, Hesselstrand R, Lehti L, Troilius Rubin A. Effects of intense pulsed light in microstomia in patients with systemic sclerosis: A pilot study. J Cosmet Laser Ther. 2017;19(3):143–148.
  20. Bennani I, Lopez R, Bonnet D, et al. Improvement of microstomia in scleroderma after carbon dioxide laser treatment. Case Rep Dermatol. 2016;8(2):142–150.
  21. Onesti MG, Fioramonti P, Carella S, Fino P, Marchese C, Scuderi N. Improvement of mouth functional disability in systemic sclerosis patients over one year in a trial of fat transplantation versus adipose-derived stromal cells. Stem Cells Int. 2016;2016:2416192. doi: 10.1155/2016/2416192
  22. Sarala K, Jayachandran S, Kumar SS. Mandibular resorption in systemic sclerosis. Indian J Rheumatol. 2016;11(1):55–56.
  23. Ramon Y, Samra H, Oberman M. Mandibular condylosis and apertognathia as presenting symptoms in progressive systemic sclerosis (scleroderma). Pattern of mandibular bony lesions and atrophy of masticatory muscles in PSS, presumably caused by affected muscular arteries. Oral Surg Oral Med Oral Pathol. 1987;63(3):269–274.
  24. Anbiaee N, Tafakhori Z. Early diagnosis of progressive systemic sclerosis (scleroderma) from a panoramic point of view: Report of three cases. Dentomaxillofac Radiol. 2011;40(7):457–462.
  25. Auluck A, Pai KM, Shetty C, Shenoi SD. Mandibular resorption in progressive systemic sclerosis: A report of three cases. Dentomaxillofac Radiol. 2005;34(6):384–386.
  26. Baron M, Hudson M, Dagenais M, et al. Relationship between disease characteristics and oral radiologic findings in systemic sclerosis: Results from a Canadian Oral Health Study. Arthritis Care Res (Hoboken). 2016;68(5):673–680.
  27. Marmary Y, Glaiss R, Pisanty S. Scleroderma: oral manifestations. Oral Surg Oral Med Oral Pathol. 1981;52(1):32–37.
  28. MacIntosh RB, Shivapuja PK, Naqvi R. Scleroderma and the temporomandibular joint: Reconstruction in 2 variants. J Oral Maxillofac Surg. 2015;73(6):1199–1210.
  29. de Figueiredo MA, de Figueiredo JA, Porter S. Root resorption associated with mandibular bone erosion in a patient with scleroderma. J Endod. 2008;34(1):102–103.
  30. Nascimento IS, Bonfa E, de Carvalho JF, et al. Clues for previously undiagnosed connective tissue disease in patients with trigeminal neuralgia. J Clin Rheumatol. 2010;15(5):205–208.
  31. Amaral TN, Peres FA, Lapa AT, Marques-Neto JF, Appenzeller S. Neurologic involvement in scleroderma: A systemic review. Semin Arthritis Rheum. 2013;43(3):335–347.
  32. Tolle SL. Scleroderma: Considerations for dental hygienists. Int J Dent Hyg. 2008;6(2):77–83.
  33. Matarese G, Isola G, Alibrandi A, et al. Occlusal and MRI characterizations in systemic sclerosis patients: A prospective study from Southern Italian cohort. Joint Bone Spine. 2016;83(1):57–62.
  34. Aliko A, Ciancaglini R, Alushi A, Tafaj A, Ruci D. Temporomandibular joint involvement in rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. Int J Oral Maxillofac Surg. 2011;40(7):
  35. Świerkot J, Kukiz-Świerkot G. Zmiany obserwowane na śluzówkach jamy ustnej w przebiegu układowych chorób tkanki łącznej. Przew Lek. 2000;3(7):73–77.
  36. Gremain V, Richard L, Langlois V, Marie I. Raynaud’s phenomenon of the tongue. Joint Bone Spine. 2017;84(2):231.
  37. Philipone E, Yoon AJ, Zegarelli D. Intraoral telangiectasias associated with Raynaud disease: A report of two cases. Quintessence Int. 2010;41(1):17–20.
  38. Bharadwaj S, Tandon P, Gohel T, et al. Gastrointestinal manifestations, malnutrition, and role of enteral and parenteral nutrition in patients with scleroderma. J Clin Gastroenterol. 2015;49(7):559–564.
  39. Yuen HK, Weng Y, Reed SG, Summerlin LM, Silver RM. Factors associated with gingival inflammation among adults with systemic sclerosis. Int J Dent Hyg. 2014;12(1):55–61.
  40. Vitali C, Bombardieri S, Jonsson R, et al; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren’s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–558.
  41. Hopcraft MS, Tan C. Xerostomia: An update for clinicians. Aust Dent J. 2010;55(3):238–244.
  42. Saleh J, Figueiredo MA, Cherubini K, Salum FG. Salivary hypofunction: An update on aetiology, diagnosis and therapeutics. Arch Oral Biol. 2015;60(2):242–255.
  43. Yuen HK, Hant FN, Hatfield C, Summerlin LM, Smith EA, Silver RM. Factors associated with oral hygiene practices among adults with systemic sclerosis. Int J Dent Hyg. 2014;12(3):180–186.
  44. Baron M, Hudson M, Tatibouet S, et al. Relationship between disease characteristic and orofacial manifestations in systemic sclerosis: Canadian Systemic Sclerosis Oral Health Study III. Arthritis Care Res (Hoboken). 2015;67(5):681–690.
  45. Wood RE, Lee P. Analysis of the oral manifestations of systemic sclerosis (scleroderma). Oral Surg Oral Med Oral Pathol. 1988;65(2):172–178.
  46. Felder R, Reveal M, Lemon S, Brown C. Testing toothbrushing ability of elderly patients. Spec Care Dentist. 1994;14(4):153–157.
  47. Leung WK, Chu CH, Mok MY, Yeung KW, Ng SK. Periodontal status of adults with systemic sclerosis: Case control study. J Periodontol. 2011;82(8):1140–1145.
  48. Poole JL, Brewer C, Rossie K, Good CC, Conte C, Steen V. Factors related to oral hygiene in persons with scleroderma. Int J Dent Hyg. 2005; 3(1):13–17.
  49. Alantar A, Cabane J, Hachulla E, et al. Recommendations for the care of oral involvement in patients with systemic sclerosis. Arthritis Care Res (Hoboken). 2011;63(8):1126–1133.
  50. Singh K, Gupta N, Gupta R, Abrahm D. Prosthetic rehabilitation with collapsible hybrid acrylic resin and permanent silicone soft liner complete denture of a patient with scleroderma-induced microstomia. J Prosthodont. 2014;23(5):412–416.
  51. Yenisey M, Kulunk T, Kurt S, Ural C. A prosthodontics management alternative for scleroderma patients. J Oral Rehabil. 2005;32(9):697–700.
© Wroclaw Medical University